DK1831252T3 - GLP-1 analog fusionsproteinformuleringer - Google Patents

GLP-1 analog fusionsproteinformuleringer

Info

Publication number: DK1831252T3
Authority: DK; Denmark
Prior art keywords: glp; fusion protein; fusion; formulations; protein formulations
Prior art date: 2004-12-22

Application number

DK05854150T

Other languages

Danish (da)

English (en)

Inventor

Rohn Lee Junior Millican

Wolfgang Glaesner

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-22

Filing date

2005-12-15

Publication date

2009-10-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36123207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1831252(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-12-15 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2009-10-05 Application granted granted Critical

2009-10-05 Publication of DK1831252T3 publication Critical patent/DK1831252T3/da

Links

238000009472 formulation Methods 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
108020001507 fusion proteins Proteins 0.000 title 1
102000037865 fusion proteins Human genes 0.000 title 1
230000004927 fusion Effects 0.000 abstract 3
230000002401 inhibitory effect Effects 0.000 abstract 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000037406 food intake Effects 0.000 abstract 1
235000012631 food intake Nutrition 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
230000030135 gastric motility Effects 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
230000000968 intestinal effect Effects 0.000 abstract 1
230000008991 intestinal motility Effects 0.000 abstract 1
208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Zoology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK05854150T 2004-12-22 2005-12-15 GLP-1 analog fusionsproteinformuleringer DK1831252T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US64169004P	2004-12-22	2004-12-22
PCT/US2005/045376 WO2006068910A1 (en)	2004-12-22	2005-12-15	Glp-1 analog fusion protein formulations

Publications (1)

Publication Number	Publication Date
DK1831252T3 true DK1831252T3 (da)	2009-10-05

Family

ID=36123207

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05854150T DK1831252T3 (da)	2004-12-22	2005-12-15	GLP-1 analog fusionsproteinformuleringer

Country Status (22)

Country	Link
US (1)	US20090232807A1 (pl)
EP (2)	EP1831252B1 (pl)
JP (1)	JP2008525452A (pl)
KR (1)	KR100879662B1 (pl)
CN (1)	CN101044162B (pl)
AT (1)	ATE435235T1 (pl)
AU (1)	AU2005319432A1 (pl)
BR (1)	BRPI0519393A2 (pl)
CA (1)	CA2589647A1 (pl)
CY (1)	CY1109269T1 (pl)
DE (1)	DE602005015257D1 (pl)
DK (1)	DK1831252T3 (pl)
EA (1)	EA011166B1 (pl)
ES (1)	ES2326906T3 (pl)
IL (1)	IL183285A0 (pl)
MX (1)	MX2007007565A (pl)
NO (1)	NO20073372L (pl)
PL (1)	PL1831252T3 (pl)
PT (1)	PT1831252E (pl)
SI (1)	SI1831252T1 (pl)
UA (1)	UA87009C2 (pl)
WO (1)	WO2006068910A1 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100888022B1 (ko) *	2006-12-21	2009-03-09	재단법인 목암생명공학연구소	면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8Ｆｃ
JP2008169195A (ja)	2007-01-05	2008-07-24	Hanmi Pharmaceutical Co Ltd	キャリア物質を用いたインスリン分泌ペプチド薬物結合体
HRP20110242T1 (hr) *	2007-07-10	2011-05-31	Eli Lilly And Company	Formulacija s fuzijskim proteinom glp-1-fc
EP2031064A1 (de) *	2007-08-29	2009-03-04	Boehringer Ingelheim Pharma GmbH & Co. KG	Verfahren zur Steigerung von Proteintitern
EP2435061A4 (en)	2009-05-28	2013-03-27	Amylin Pharmaceuticals Inc	DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
WO2011056713A2 (en)	2009-11-03	2011-05-12	Amylin Pharmaceuticals, Inc.	Glp-1 receptor agonist compounds for obstructive sleep apnea
US9487570B2 (en) *	2010-05-17	2016-11-08	Betta Pharmaceuticals Co., Ltd	Glucagon like peptide analogs, composition, and method of use
CN102533655A (zh) *	2010-12-21	2012-07-04	青岛黄海制药有限责任公司	高效表达人源重组蛋白GLP1/Fc的CHO-S细胞株及其建立方法
EP2654767A4 (en)	2010-12-22	2014-05-21	Amylin Pharmaceuticals Inc	GLP-1 RECEPTOR AGONISTS FOR ISLAND CELL TRANSPLANTATION
KR20130049671A (ko)	2011-11-04	2013-05-14	한미사이언스 주식회사	생리활성 폴리펩타이드 결합체 제조 방법
AR094821A1 (es)	2012-07-25	2015-09-02	Hanmi Pharm Ind Co Ltd	Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
US10441665B2 (en)	2012-07-25	2019-10-15	Hanmi Pharm. Co., Ltd.	Liquid formulation of long acting insulinotropic peptide conjugate
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja)	2012-12-21	2016-03-03	サノフイ	二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
CN104173275A (zh) *	2013-05-21	2014-12-03	深圳翰宇药业股份有限公司	度拉鲁肽注射剂及其制备方法
CN104371019B (zh) *	2013-08-13	2019-09-10	鸿运华宁（杭州）生物医药有限公司	一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
UA130573C2 (uk) *	2014-03-31	2026-03-25	Ханмі Фарм. Ко., Лтд.	Спосіб покращення розчинності білка та пептиду із застосуванням зв'язування з fc-фрагментом імуноглобуліну
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN104327187B (zh) *	2014-10-11	2018-06-08	上海兴迪金生物技术有限公司	一种重组人GLP-1-Fc融合蛋白
WO2016077806A1 (en) *	2014-11-13	2016-05-19	AskGene Pharma, Inc.	Fusion proteins with dual receptor agonist activities
ES2833099T3 (es)	2015-02-11	2021-06-14	Gmax Biopharm Llc	Preparación de disolución estabilizada de una proteína de fusión de un anticuerpo de GLP-1R farmacéutica
US10993993B2 (en) *	2015-05-28	2021-05-04	Immunoforge Co., Ltd.	Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CR20180378A (es)	2015-12-23	2018-12-06	Amgen Inc	Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
GB201621987D0 (en) *	2016-12-22	2017-02-08	Archer Virgil L See Archer Sheri A Arecor Ltd	Novel composition
KR102781241B1 (ko) *	2017-01-17	2025-03-14	암젠 인크	위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
MX2019013919A (es)	2017-06-20	2020-01-21	Amgen Inc	Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
JP7250706B2 (ja)	2017-06-21	2023-04-03	アムジエン・インコーポレーテツド	胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
CA3071337A1 (en)	2017-08-15	2019-02-21	Kindred Biosciences, Inc.	Igg fc variants for veterinary use
MX2020005231A (es)	2017-11-21	2020-08-24	Lilly Co Eli	Metodos de uso y composiciones que contienen dulaglutida.
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TWI705820B (zh)	2018-06-22	2020-10-01	美商美國禮來大藥廠	Gip/glp1促效劑組合物
CN113613629A (zh)	2019-03-15	2021-11-05	伊莱利利公司	防腐的制剂
CA3056663C (en)	2019-04-05	2022-10-18	Jeffrey S. RIESMEYER	Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
US20210187077A1 (en) *	2019-12-23	2021-06-24	Idaho State University	GLP-1 Agonist Conjugates for Sustained Glycemic Control
CN116478298A (zh) *	2021-12-31	2023-07-25	广东东阳光药业有限公司	Glp-1和gdf15的融合蛋白及其用途
MX2024005969A (es) *	2022-05-30	2024-06-11	Zealand Pharma As	Formulaciones liquidas de analogos de amilina.
WO2026021575A1 (zh) *	2024-07-26	2026-01-29	鸿运华宁（杭州）生物医药有限公司	一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5118666A (en) *	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
HUT76369A (en) *	1994-07-29	1997-08-28	Smithkline Beecham Corp	Novel soluble protein compounds
GB9511935D0 (en) *	1995-06-13	1995-08-09	Smithkline Beecham Plc	Novel compound
US6376653B1 (en) *	1998-09-28	2002-04-23	Smithkline Beecham Plc	Tie2 antagonist antibodies
ES2311560T3 (es) *	2000-12-07	2009-02-16	Eli Lilly And Company	Proteinas de fusion glp-1.
WO2002079415A2 (en) *	2001-03-30	2002-10-10	Lexigen Pharmaceuticals Corp.	Reducing the immunogenicity of fusion proteins
US20030191056A1 (en) *	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP4629047B2 (ja) *	2003-06-12	2011-02-09	イーライリリーアンドカンパニー	Ｇｌｐ−１アナログ複合タンパク質

2005
- 2005-12-15 PT PT05854150T patent/PT1831252E/pt unknown
- 2005-12-15 EP EP05854150A patent/EP1831252B1/en not_active Expired - Lifetime
- 2005-12-15 WO PCT/US2005/045376 patent/WO2006068910A1/en not_active Ceased
- 2005-12-15 MX MX2007007565A patent/MX2007007565A/es active IP Right Grant
- 2005-12-15 EP EP09160182A patent/EP2168982A1/en not_active Withdrawn
- 2005-12-15 CA CA002589647A patent/CA2589647A1/en not_active Abandoned
- 2005-12-15 SI SI200530779T patent/SI1831252T1/sl unknown
- 2005-12-15 JP JP2007548310A patent/JP2008525452A/ja not_active Withdrawn
- 2005-12-15 AU AU2005319432A patent/AU2005319432A1/en not_active Abandoned
- 2005-12-15 KR KR1020077014068A patent/KR100879662B1/ko not_active Expired - Lifetime
- 2005-12-15 DK DK05854150T patent/DK1831252T3/da active
- 2005-12-15 UA UAA200706803A patent/UA87009C2/ru unknown
- 2005-12-15 EA EA200701364A patent/EA011166B1/ru not_active IP Right Cessation
- 2005-12-15 ES ES05854150T patent/ES2326906T3/es not_active Expired - Lifetime
- 2005-12-15 CN CN2005800355972A patent/CN101044162B/zh not_active Ceased
- 2005-12-15 BR BRPI0519393-1A patent/BRPI0519393A2/pt active Search and Examination
- 2005-12-15 AT AT05854150T patent/ATE435235T1/de active
- 2005-12-15 DE DE602005015257T patent/DE602005015257D1/de not_active Expired - Lifetime
- 2005-12-15 PL PL05854150T patent/PL1831252T3/pl unknown
- 2005-12-15 US US11/720,939 patent/US20090232807A1/en not_active Abandoned
2007
- 2007-05-17 IL IL183285A patent/IL183285A0/en unknown
- 2007-06-29 NO NO20073372A patent/NO20073372L/no not_active Application Discontinuation
2009
- 2009-08-06 CY CY20091100832T patent/CY1109269T1/el unknown

Also Published As

Publication number	Publication date
EP1831252A1 (en)	2007-09-12
PL1831252T3 (pl)	2009-11-30
BRPI0519393A2 (pt)	2009-01-20
PT1831252E (pt)	2009-09-17
US20090232807A1 (en)	2009-09-17
SI1831252T1 (sl)	2009-12-31
EA011166B1 (ru)	2009-02-27
CN101044162A (zh)	2007-09-26
IL183285A0 (en)	2007-09-20
MX2007007565A (es)	2007-07-24
KR20070089187A (ko)	2007-08-30
EA200701364A1 (ru)	2007-10-26
EP2168982A1 (en)	2010-03-31
UA87009C2 (ru)	2009-06-10
KR100879662B1 (ko)	2009-01-20
JP2008525452A (ja)	2008-07-17
WO2006068910A1 (en)	2006-06-29
AU2005319432A1 (en)	2006-06-29
CY1109269T1 (el)	2014-07-02
HK1107570A1 (en)	2008-04-11
DE602005015257D1 (pl)	2009-08-13
EP1831252B1 (en)	2009-07-01
CN101044162B (zh)	2010-10-27
ES2326906T3 (es)	2009-10-21
ATE435235T1 (de)	2009-07-15
CA2589647A1 (en)	2006-06-29
NO20073372L (no)	2007-07-16

Publication	Publication Date	Title
NO20073372L (no)	2007-07-16	GLP-1-analoge fusjonsproteinformuleringer
TW200507870A (en)	2005-03-01	GLP-1 analog fusion proteins
NO20076415L (no)	2007-12-12	GLP-1 pegylerte forbindelser
UA92451C2 (en)	2010-11-10	Polyethelene glycol link glp-1 compounds
EA200601555A1 (ru)	2007-02-27	Замещенные индазол-о-глюкозиды
EA200601554A1 (ru)	2006-12-29	Замещенные индол-о-глюкозиды
WO2005012318A3 (en)	2005-12-15	Substituted fused heterocyclic c-glycosides
DE602005016917D1 (de)	2009-11-12	Fgf-21-fusionsproteine
UA86042C2 (en)	2009-03-25	Substituted indazole-o-glucosides
WO2006042152A3 (en)	2007-05-18	Vasoactive intestinal polypeptide pharmaceuticals
WO2002044113A3 (en)	2002-09-12	Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2007044591A3 (en)	2007-11-29	Vasoactive intestinal polypeptide pharmaceuticals
DE50210906D1 (de)	2007-10-25	Arzneimittel enthaltend deuterium zur behandlung der zuckerkrankheit
PL1522312T3 (pl)	2007-08-31	Biologicznie stabilna ciekła kompozycja FVIII lub vWF, lub kompleksu FVIII/vWF pochodzenia ludzkiego
WO2001087468A8 (en)	2003-03-06	Microfiltration using activated carbon
WO2003024946A3 (en)	2003-12-04	Oxamate derivatives containing a variously substituted nitrogen heterocycle
NO20030021D0 (no)	2003-01-03	Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
DK1748043T3 (da)	2008-12-08	Polysubstituerede 1,1-pyridinyloxycyclopropanaminderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
RU2005106768A (ru)	2006-08-20	Способ лечения хронических гонартринов у больных остеоартрозом